Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23343844 | 0.86 | NOS3 (0.46) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL15723889 | 0.85 | NOS3 (0.42) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL29857523 | 0.84 | NOS3 (0.45) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL20482609 | 0.84 | NOS3 (0.50) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL2084135 | 0.84 | NOS3 (0.50) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL24873408 | 0.84 | NOS3 (0.45) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL30140878 | 0.84 | NOS3 (0.50) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL23747533 | 0.84 | NOS3 (0.50) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL506508 | 0.84 | NOS3 (0.45) | NOS3NOS1NOS2NPC1PLAU | |
| SCHEMBL507147 | 0.84 | NOS3 (0.45) | NOS3NOS1NOS2NPC1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | claimed |
| EP-1891074-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006138682-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024081904-A1 | METHODS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024059096-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | NOS3 1496/4885NOS1 1755/4885NOS2 2162/4885 |
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | NOS3 3737/4885NOS1 3170/4885NOS2 3199/4885 |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | ARRB1, FPR1, OPRL1 | NOS3 902/4885NOS1 1526/4885NOS2 1311/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | NOS3 4605/4885NOS1 4649/4885NOS2 4513/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | NOS3 3929/4885NOS1 3193/4885NOS2 3960/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | NOS3 2003/4885NOS1 1860/4885NOS2 652/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | NOS3 654/4885NOS1 852/4885NOS2 1042/4885 |
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | CCR1, MSR1, CCR2 | NOS3 11/4885NOS1 4/4885NOS2 5/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | NOS3 1368/4885NOS1 1250/4885NOS2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.